New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Zevra Therapeutics

Contributing Author

Recent Articles by Zevra Therapeutics

Oct-06	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ZVRA GlobeNewswire
Sep-18	Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA (arimoclomol) and OLPRUVA (sodium phenylbutyrate) ZVRA GlobeNewswire
Sep-04	Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) ZVRA GlobeNewswire
Aug-28	Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) ZVRA GlobeNewswire
Aug-26	Zevra Therapeutics to Participate at Upcoming Investor Conferences in September ZVRA GlobeNewswire
Aug-12	Zevra Reports Second Quarter 2025 Financial Results and Corporate Update ZVRA GlobeNewswire
Aug-06	Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference ZVRA GlobeNewswire
Aug-04	Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call ZVRA GlobeNewswire
Jul-28	Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C ZVRA GlobeNewswire
Jul-18	Zevra Therapeutics Announces MIPLYFFA and OLPRUVA Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) ZVRA GlobeNewswire
Jul-16	Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism ZVRA GlobeNewswire
Jul-11	Zevra Therapeutics Announces MIPLYFFA (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference ZVRA GlobeNewswire
May-29	Zevra Announces Final Results of 2025 Annual Meeting of Stockholders ZVRA GlobeNewswire
May-21	All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees ZVRA GlobeNewswire
May-13	Zevra Reports First Quarter 2025 Financial Results and Corporate Update ZVRA GlobeNewswire
May-06	Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call ZVRA GlobeNewswire
May-01	Zevra Therapeutics to Participate in the Citizens Life Science Conference ZVRA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.